Home›Legal›CJC-1295 in New York
CJC-1295 in New York: Legal Status & Provider Guide (2026)
Quick Answer
CJC-1295 is a prescription substance in the United States. CJC-1295 is a synthetic GHRH analog with no FDA approval and no bulk compounding authorization. Federal compliance for compounding facilities is uncertain. Clinical use occurs in a regulatory gray area. In New York, compounding is governed by the New York State Board of Pharmacy (NYSBP). New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
Federal Legal Status
FDA Approval Status
Not FDA-approved. Not on the FDA 503A or 503B bulk substances lists. CJC-1295 (with or without DAC) is an unapproved research peptide.
Compounding Pharmacy Rules (Federal)
CJC-1295 is not on the FDA bulk substances list for 503A or 503B compounding. FDA has issued guidance indicating that unapproved peptides like CJC-1295 may not be lawfully compounded by facilities subject to FDA oversight. Providers offering it operate in a legally uncertain space under federal law.
Also Known As
Modified GRF (1–29) · Mod GRF 1–29 · DAC:GRF
Primary Research Areas
- Growth hormone release
- Anti-aging
- Body composition
- Muscle recovery
New York Pharmacy Board & Compounding Rules
Compounding Overview
New York has among the most stringent pharmacy and prescribing regulations in the country. The New York State Board of Pharmacy enforces USP 797 and 795 standards and requires all compounding pharmacies to meet detailed quality and documentation requirements. New York has been particularly active in enforcing against unapproved compounded medications. In-state telehealth peptide providers are subject to strict New York Medical Board oversight.
Notable Rules
- New York requires compounding pharmacies to register separately for sterile compounding.
- The New York Department of Health has enforcement authority over unlicensed pharmaceutical activity.
- New York has stricter-than-federal requirements for documentation of medical necessity for compounded preparations.
- Interstate prescribing into New York requires a New York state license.
- New York and Pennsylvania maintain reciprocal pharmacy licensure recognition for some categories.
Prescribing Requirements in New York
New York requires a collaborative practice agreement for nurse practitioners prescribing controlled substances, but NPs with full prescriptive authority may prescribe most compounded peptides independently. Physician assistants require physician supervision for prescribing. New York's telehealth prescribing rules require prescribers to hold a New York license; interstate telemedicine prescribing is tightly regulated.
About CJC-1295
CJC-1295 is a synthetic analog of GHRH designed for extended half-life through Drug Affinity Complex (DAC) technology. The DAC version binds to albumin in the bloodstream, extending its half-life significantly compared to sermorelin. It is often studied in combination with ipamorelin.
For more research information, mechanism of action, and provider availability, see the CJC-1295 research profile on PeptideBase.
Frequently Asked Questions
- What is the difference between CJC-1295 with DAC and without DAC?
- CJC-1295 with DAC binds to albumin and has a half-life of approximately 1–2 weeks, allowing less frequent dosing. CJC-1295 without DAC (also called Modified GRF 1-29) has a much shorter half-life of approximately 30 minutes, similar to sermorelin, and requires more frequent administration.
CJC-1295 Providers in New York
No providers currently listed in New York for CJC-1295. Browse the full directory to find providers offering CJC-1295.
Browse all CJC-1295 providers →CJC-1295 Legal Status in Other States
Pharmacy board rules and compounding regulations vary by state. Compare CJC-1295 legal status across other major markets:
Content review: This educational overview is prepared by the PeptideBase editorial team and reviewed for factual accuracy. Reviewer byline coming soon (gated on 4.4). Last updated: .